Literature DB >> 23959473

Lost miRNA surveillance of Notch, IGFR pathway--road to sarcomagenesis.

K Galoian, T Guettouche, B Issac, L Navarro, H T Temple.   

Abstract

The goal of this study was to compare and analyze differentially expressed miRNA and their targets in human chondrosarcoma JJ012 and chondrocytes C 28 cell lines (control) to elucidate deregulation of major signal transduction pathways involved in sarcomagenesis. Total RNA extraction was followed by analyzing RNA quality and integrity. Exiqon human miRNA panel of 743 unique miRNA assays and Illumina microarray HT-12 platform and quantitative reverse transcriptase–PCR verification of targets were performed. The results from human miRNA Exiqon arrays with biological triplicates indicated 28 significant miRNAs (P value ≤0.01). A total 3,045 target genes were derived from the miRWalk database for these 28 miRNAs with 587 common and 2,458 unique target genes. The results of our analyses of the significantly downregulated and upregulated miRNAs in chondrosarcoma cell line indicated the predominant dysregulation of NOTCH, insulin-like growth factor receptor (IGFR), and downstream rat sarcoma, and Src pathways, compared to control. Among the upregulated targets for upregulated miRNAs were the cluster of cancer testis antigen (CTA) genes, located on X chromosome, and their expression was correlated to IGFR pathway activity. Based on our observations, lost miRNA surveillance of NOTCH and IGFR pathways is involved in and leads to sarcomagenesis. We conclude that upregulation of CTA genes is due to hypomethylation that are controlled by epi-miRNAs. We do not preclude the possibility that the upregulated miRNAs, which target CTA genes located in adjacent regions in chromosome X, are epi-miRNAs that influence target gene expression by directly regulating epigenetic processes. Future endeavors will be directed towards understanding the posttranscriptional modifications that affect miRNA expression in sarcomas.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 23959473     DOI: 10.1007/s13277-013-1068-5

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  55 in total

1.  Allelotype of pediatric rhabdomyosarcoma.

Authors:  M Visser; C Sijmons; J Bras; R J Arceci; M Godfried; L J Valentijn; P A Voûte; F Baas
Journal:  Oncogene       Date:  1997-09       Impact factor: 9.867

2.  LNA-mediated microRNA silencing in non-human primates.

Authors:  Joacim Elmén; Morten Lindow; Sylvia Schütz; Matthew Lawrence; Andreas Petri; Susanna Obad; Marie Lindholm; Maj Hedtjärn; Henrik Frydenlund Hansen; Urs Berger; Steven Gullans; Phil Kearney; Peter Sarnow; Ellen Marie Straarup; Sakari Kauppinen
Journal:  Nature       Date:  2008-03-26       Impact factor: 49.962

3.  Expression of MAGE-A1 mRNA is associated with gene hypomethylation in hepatocarcinoma cell lines.

Authors:  Jiang Xiao; Hong-Song Chen; Ran Fei; Xu Cong; Li-ping Wang; Yan Wang; Dong Jiang; Lai Wei; Yu Wang
Journal:  J Gastroenterol       Date:  2005-07       Impact factor: 7.527

4.  mTORC1 inhibition and ECM-cell adhesion-independent drug resistance via PI3K-AKT and PI3K-RAS-MAPK feedback loops.

Authors:  Karina Galoian; H T Temple; Armen Galoyan
Journal:  Tumour Biol       Date:  2012-01-14

Review 5.  Notch: a key regulator of tumor angiogenesis and metastasis.

Authors:  Alejandro Garcia; Jessica J Kandel
Journal:  Histol Histopathol       Date:  2012-02       Impact factor: 2.303

6.  Activation of human cancer/testis antigen gene, XAGE-1, in tumor cells is correlated with CpG island hypomethylation.

Authors:  Jun Hee Lim; Sang-Pyo Kim; Edward Gabrielson; Yong Bok Park; Jong-Wook Park; Taeg Kyu Kwon
Journal:  Int J Cancer       Date:  2005-08-20       Impact factor: 7.396

7.  The human let-7a-3 locus contains an epigenetically regulated microRNA gene with oncogenic function.

Authors:  Bodo Brueckner; Carlo Stresemann; Ruprecht Kuner; Cora Mund; Tanja Musch; Michael Meister; Holger Sültmann; Frank Lyko
Journal:  Cancer Res       Date:  2007-02-15       Impact factor: 12.701

8.  Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers.

Authors:  George Adrian Calin; Cinzia Sevignani; Calin Dan Dumitru; Terry Hyslop; Evan Noch; Sai Yendamuri; Masayoshi Shimizu; Sashi Rattan; Florencia Bullrich; Massimo Negrini; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-18       Impact factor: 11.205

Review 9.  Insulin-like growth factor-I receptor signal transduction and the Janus Kinase/Signal Transducer and Activator of Transcription (JAK-STAT) pathway.

Authors:  Eddy Himpe; Ron Kooijman
Journal:  Biofactors       Date:  2009 Jan-Feb       Impact factor: 6.113

10.  Extraskeletal myxoid chondrosarcoma with small bowel metastasis causing bowel obstruction.

Authors:  Ernesto Bustinza-Linares; Francisco Socola; Vinicius Ernani; Shelly A Miller; Jonathan C Trent
Journal:  Case Rep Oncol Med       Date:  2012-11-18
View more
  4 in total

1.  Effect of cytostatic proline rich polypeptide-1 on tumor suppressors of inflammation pathway signaling in chondrosarcoma.

Authors:  Karina Galoian; Shihua Luo; Amir Qureshi; Parthik Patel; Rachel Price; Ashlyn S Morse; Gor Chailyan; Silva Abrahamyan; H T Temple
Journal:  Mol Clin Oncol       Date:  2016-09-02

2.  Mice with Trp53 and Rb1 deficiency in chondrocytes spontaneously develop chondrosarcoma via overactivation of YAP signaling.

Authors:  Yang Li; Shuting Yang; Yang Liu; Shuying Yang
Journal:  Cell Death Dis       Date:  2022-06-27       Impact factor: 9.685

3.  Genome-wide mRNA and miRNA expression data analysis to screen for markers involved in sarcomagenesis in human chondrosarcoma cell lines.

Authors:  Biju Issac; Karina Galoian; Toumy Guettouche; Loida Navarro; H Thomas Temple
Journal:  Genom Data       Date:  2014-10-13

Review 4.  Chondrosarcoma: A Rare Misfortune in Aging Human Cartilage? The Role of Stem and Progenitor Cells in Proliferation, Malignant Degeneration and Therapeutic Resistance.

Authors:  Karen A Boehme; Sabine B Schleicher; Frank Traub; Bernd Rolauffs
Journal:  Int J Mol Sci       Date:  2018-01-21       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.